For the molecular mechanisms of melittin as anticancer agent, Duffy et al. demonstrated that melittin induced cancer cell death, especially in TNBC and HER2 breast cancers, by inducing that the EGFR and HER2 could not be phosphorylated in the cell membrane of breast cancer cells (Duffy et al., 2020). This evidence concerns the gene ERBB2 and breast carcinoma.